| Document |
Document Title |
|
JP5923038B2 |
[PROBLEMS] The present invention providers a novel alkoxyimino derivative or a salt thereof, as well as to a pest control agent containing the derivative or salt thereof as an active ingredient, which shows an excellent pest control effe...
|
|
JP5918538B2 |
This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R1 and R2 are hydrogen, alkyl, or aryl radicals.
|
|
JP2016053055A |
To provide a prophylactic or therapeutic agent for diabetes, diabetic complications, diabetic microangiopathy complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, ca...
|
|
JP5897186B2 |
This invention is directed to a compound of formula (I):wherein R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising the compound, intermediates and processes for making said compounds, and the use of the compound...
|
|
JP5848698B2 |
The present invention relates to inhibitors of 11- ß-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, centr...
|
|
JP5839317B2 |
|
|
JP5837421B2 |
|
|
JP5832447B2 |
The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invent...
|
|
JP2015205939A |
To provide a tetracycline derivative for treatment of bacteria infection, virus infection and parasite infection.The invention at least partially relates to a substituted tetracycline compound of the formula (I), where X is CHC(RY'Y), CR...
|
|
JP5815033B2 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1 to R3 and X have the significances given herein. The present invention is also directed to processe...
|
|
JP2015528009A |
Certain histone deacetylase (HDAC) inhibitors, compositions thereof, and methods of use thereof are provided. The present invention provides a pharmaceutical composition comprising a compound described herein or a pharmaceutically accept...
|
|
JP5779142B2 |
The invention is directed to the cross-metathesis and ring-closing metathesis reactions between geminal disubstituted olefins and terminal olefins, wherein the reaction employs a Ruthenium or Osmium metal carbene complex. Specifically, t...
|
|
JP5769627B2 |
The present invention relates to an improved process for the preparation of the active pharmaceutical ingredient vorinostat. In particular it relates to a process for preparing vorinostat substantially free from impurities, involving sub...
|
|
JP2015145401A |
To provide compounds for medicament to inhibit histone deacetylase.This invention provides a compound such as phenyl hydroxamic acid substituted with a group comprising, for example, oxazepine, diazepine, thiazepine skeletons, pyrimidine...
|
|
JP5763621B2 |
Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug re...
|
|
JP5746860B2 |
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and c...
|
|
JP5746196B2 |
Compound selected from 4-(2(S)-benzoylamino-3-naphthalen-2-yl-propionylamino)-N-hyd
roxy-benzamide and benzo[1,3]dioxole-5-carboxylic acid [1(S)-(4-hydroxycarbamoyl-phenylcarbamoyl)-2-naphthalen-2-yl
-ethyl]-amide, for use in the treatme...
|
|
JP5732408B2 |
Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH— Or —CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one ...
|
|
JP5730581B2 |
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for det...
|
|
JP5702681B2 |
Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.
|
|
JP5676600B2 |
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for det...
|
|
JP5675071B2 |
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositio...
|
|
JPWO2012165262A1 |
The present invention provides a novel compound effective for the treatment of blood cancer, particularly multiple myeloma, which is also effective for suppressing SP cells (Side Population Cells) that cause cancer recurrence. With the g...
|
|
JP2015504056A |
Described herein are compounds that inhibit the activity of histone deacetylase 8 (HDAC8) and pharmaceutical compositions containing such compounds. Also described herein are methods of using such HDAC8 inhibitors alone or in combination...
|
|
JP5648083B2 |
A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group deriv...
|
|
JP2014237669A |
To provide a method of producing a crystal of suberoylanilide hydroxamic acid (SAHA) which induces selectively final differentiation of neoplastic cells, termination of cell growth and/or apoptosis and is a histone deacetylase inhibitor ...
|
|
JP2014529579A |
The present invention relates to prodrug derivatives of pentamidine and to their use for the treatment and / or prevention of diseases, particularly tumors, leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP) and malaria.
|
|
JP5619284B2 |
The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of...
|
|
JP5607021B2 |
The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzy...
|
|
JP2014177468A |
To provide a compound treating gram-negative infections by inhibiting activity of an enzyme uridyldiphospho-3-O-(R-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), which is the enzyme in the first committed step in the synthesis ...
|
|
JP2014524432A |
The present invention relates to substitution カルバモ ylmethoxy and カルバモ ylmethyl チオベンズ amide compound (I) s, those stereoisomeric forms, salt, a tautomerism object, N-オキシド, and the constituent containing t...
|
|
JP5586896B2 |
The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositio...
|
|
JP5586961B2 |
Provided herein are self-assembling compounds that can form ion channels in lipid bilayers or cell membranes and ion-channel-forming compositions comprising the self-assembling compounds. Also provided are methods of making and using the...
|
|
JP5567650B2 |
Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-
dioxo-1 (2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of ...
|
|
JP5550993B2 |
Novel monoamidine, monoamidoxime and bisamidine curatives, co-curatives and cure accelerators are provided for use with perfluoroelastomeric compositions as well as novel synthesis methods for making monoamidine- and monoamidoxime-based ...
|
|
JP5550650B2 |
The present application describes organic compounds of a general formula: and salts, and isomers thereof, wherein R, R2 and R3 are defined in the specification. The compounds are useful for treating a gram-negative bacterial infection.
|
|
JP2014129553A |
To provide improved curatives capable of more easily dispersing in and more quickly curing perfluoroelastomers, particularly cyano curable perfluoroelastomers.Novel monoamidine, monoamidoxime and bisamidine curatives, co-curatives and cu...
|
|
JP5539864B2 |
Antibacterial compounds of formula (I) are provided, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infectio...
|
|
JP2014514259A |
The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compound...
|
|
JP2014111615A |
To provide compounds for inhibiting histone deacetylase enzymatic activity, and prodrugs thereof, for intervening in cell cycle regulation and therapeutic potential.This invention provides a compound of the formula Cy-L2-Ar-Y2-C(O)N(Rx)-...
|
|
JP5524215B2 |
The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A...
|
|
JP2014101380A |
To provide deacetylase inhibitors and uses thereof.The present invention provides novel compounds of formula (I) and pharmaceutical compositions thereof. The inventive compounds are useful as deacetylase inhibitors (e.g., histone deacety...
|
|
JP2014511355A |
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
|
|
JP5477893B2 |
Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.
|
|
JP2014509291A |
Surface-modified zirconia nanoparticles include zirconia nanoparticles and surface-modifying ligands attached to the zirconia nanoparticles. The ligand includes a hydroxamate functionality, and either a reactive group or an oligomeric gr...
|
|
JP5448383B2 |
|
|
JP5441416B2 |
In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel bifunctional, trifunctional, or multifunctional compounds for inhibiting histone deacety...
|
|
JP5421238B2 |
Provided is a new compound with excellent MMP inhibitory effect and reduced side-effects. The compound is a matrix metalloproteinase inhibitor with, as an active ingredient, the hydroxamic acid derivative represented by general formula (...
|
|
JP5405820B2 |
Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers: Wherein R 1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more int...
|
|
JP5399422B2 |
The present invention provides novel synthesis's for obtaining a protecting group aminoxy PEG-6 linker from cost effective, and readily available starting materials and chemicals or modified polyethylene glycols. More specifically, a nov...
|
